Stemnovate’s innovative Liver on-chip technology takes into account variants in the patient’s genetic that enable precision, carefully targeted drug development from the early stages of the process – resulting in safer and more cost-effective drug discovery.
Our platforms facilitate in-depth genomic, transcriptomic and bioinformatic analysis on iPS derived hepatocytes (HLCs) complementing cell line studies to determine the zygosity, cytochrome P450 (CYPs) expression and key pluripotency, hepatic transcripts and membrane transporters within a given population groups complimenting the traditional cell based assays.
FDA is already evaluating ‘on the chip technologies’ for effectiveness for drug discovery , microbiology and toxicology.
Induced Pluripotent stem cell lines
Human & Multispecies Primary cells
Cell culture & analysis package
ServicesCell Reprogramming
Cell Differentiation
Application Development
DataPharmacogenomic Data
Single Nucleotide Polymorphism
Transcriptomics
Pharmacokinetic/Pharmacodynamic Data
DeviceMicrophysiological systems
Microfluidic design, prototyping and manufacturing
Biosensing and Automation
Our clients say
You are doing some amazing and important work at Stemnovate, we are happy to be associated with your project.“
Thank you for your presentations, they were really great and stimulating. I am very happy we met and that we could get the cells in culture!“
Pharma CASE STUDIES
Prof Ciro Semprebon will be working in partnership with Stemnovate on the prestigious EPSRC grant project for advancing SLIPS technology.
Stemnovate has partnered with multinational collaborators on a project coordinated by MEDES Institute of space medicine and physiology.